NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that Anil Diwan, PhD, President of the Company has been asked to present a talk at NanoBusiness2009 - the 8th annual NanoBusiness Conference.
Dr. Diwan will speak about the nanoviricides™ drug pipeline, including Influenza (FluCide™), HIV (HIVCide™), antiviral eye-drops (EKCCide™) and the newly initiated Herpes “cold sores” and genital herpes preclinical stage program. He will speak about how the nanoviricides technology platform has enabled rapid drug development against a number of diseases caused by many different viruses. Dr. Diwan will speak in the session entitled “New Pharmaceutical Compounds Based on Soft Nanotechnology: Novel Classes of Therapeutics” on Wednesday, September 9. The Conference is being held at the McCormick Place, Chicago, IL.
This is the 8th annual conference on the business of nanotechnology organized by the NanoBusiness Alliance. The NanoBusiness Alliance mission is to create a collective voice for the advancing nanotechnology industry and develop a range of initiatives to support the nanotechnology business community.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital herpes, viral diseases of the eye including EKCand herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.